Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PATH STROKE C: Ticagrelor vs Clopidogrel in Acute Ischemic Stroke with Clopidogrel Resistance
NCT06853535Phase 3Recruiting
- Sponsor
- Sichuan Provincial People's Hospital
- Start
- May 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of ticagrelor in ischemic stroke and Transient Ischemic Attack (TIA) (2 arms), sponsored by Sichuan Provincial People's Hospital. Primary endpoint: Recurrent stroke (including ischemic and hemorrhagic stroke) at 90 days. Started May 2025; status: recruiting.
02
Drugs
ticagrelor
03
Conditions
ischemic strokeTransient Ischemic Attack (TIA)
Beyond the preview
Go deeper on NCT06853535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06853535.